7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,598.08

+356.76

+0.46%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

LSE GBp

Ondine Biomedical Inc. (OBI.L)

9.75 0.00 (0.00%)

At close: October 30 at 4:35:20 PM GMT

Loading Chart for OBI.L

Chart Range Bar

Interval:

In partnership with ChartIQ

Ondine reports negligible adverse event rate for nasal light therapy in 5,188-patient trial - UPDATE

Ondine reports negligible adverse event rate for nasal light therapy in 5,188-patient trial - UPDATE

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value - UPDATE

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value - UPDATE

Ondine Biomedical targets US regulatory milestone after £10m raise and positive Phase 3 results

Ondine Biomedical targets US regulatory milestone after £10m raise and positive Phase 3 results

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

Galliford Try, Ondine Biomedical, Optima Health, ACG Metals, Rockfire Resources, Quantum Helium

Galliford Try, Ondine Biomedical, Optima Health, ACG Metals, Rockfire Resources, Quantum Helium

Ondine Biomedical raises £10m for international commercial expansion

Ondine Biomedical raises £10m for international commercial expansion

Ondine Biomedical pauses trading to raise fresh investment after positive phase III result

Ondine Biomedical pauses trading to raise fresh investment after positive phase III result

Ondine Biomedical taps NHS intensive care data to prove Steriwave pays its way

Ondine Biomedical taps NHS intensive care data to prove Steriwave pays its way

Ondine wins five Ontario hospitals for Steriwave infection treatment

Ondine wins five Ontario hospitals for Steriwave infection treatment

Ondine Biomedical CTO: LANTERN results 'change the entire nature of the company'

Ondine Biomedical CTO: LANTERN results 'change the entire nature of the company'

Ondine Biomedical gains 5% as LANTERN clears phase III hurdle

Ondine Biomedical gains 5% as LANTERN clears phase III hurdle

Mobilize your Website

View Site in Mobile | Classic

Share by: